Beyond Boston: Choosing the Right Biopharma Hubs in North America

For decades, Boston and San Francisco Bay Area defined biopharma expansion in North America. Many companies chose them as default entry points. However, capital markets now demand efficiency over reputation. High rents and talent wars create pressure in Boston. Lab space saturation adds further constraints. Early-stage companies face rising barriers to entry. As a result, companies now prioritize pragmatic strategies. Wise decision-makers increasingly see North America as specialized clusters. Each cluster serves distinct functions across the value chain. 

The best entry point depends on company stage and strategy. Companies must assess whether they need cost-efficient R&D, clinical acceleration, or tax optimization. There is no single best location. There are only the most suitable strategic footholds. This article highlights five emerging destinations. Each offers unique advantages for biopharma expansion.

Calgary: The “Sweet Spot” for Biotech R&D Acceleration and Capital Efficiency

Calgary Emerges as Canada’s Biotech Transformation Hub with Strategic Advantages

Positioned as a rising biotech transformation hub in Canada, Calgary is emerging as a strategic location where geographic advantage meets operational efficiency. For preclinical and early-stage biotech companies, the city offers an ideal balance between R&D productivity and capital preservation. According to the BioAlberta Life Sciences in Alberta 2025, Alberta’s life sciences sector is entering a phase of rapid expansion, contributing more than CAD 4.8 billion to GDP in 2024. Calgary’s core strength lies in its relatively low operating costs and high quality of life. Office rents and talent salaries are over 40% lower than in major U.S. biotech hubs such as Boston and San Francisco. This cost advantage typically allows biotech startups to extend their seed funding runway by an additional six to twelve months.

The Alberta Innovates 2025–2028 strategic plan identifies health, agriculture, and life sciences as priority areas for cross-sector innovation. It places particular emphasis on the commercialization of next-generation therapeutics, biologics, and regenerative medicine. In parallel, Alberta’s 2026 provincial budget allocates CAD 280 million over three years to enhance diagnostic imaging infrastructure. It also commits CAD 60 million to upgrade laboratory services. These investments will integrate artificial intelligence technologies and create a favorable environment for digital health innovation.

Calgary is also actively transforming its traditional strengths, such as agriculture, into drivers of digital health and biotechnology. The Life Sciences Innovation Hub at University of Calgary provides research-intensive companies with laboratory space, infrastructure, and venture support. It has become a key commercialization platform for life sciences in Western Canada. The Calgary Cancer Centre, the second-largest cancer care facility in North America, is also located in the city, further strengthening its clinical and translational capabilities.

In addition, Alberta has established clinical trial coordination bodies such as Clinical Trials Alberta and Alberta Cancer Clinical Trials. These platforms support international companies in setting up local operations and conducting multi-center studies. Meanwhile, the ADEPT platform (Alberta Diagnostic Ecosystem Platform for Translation) provides translational support in diagnostics. It integrates clinical expertise, biospecimen resources, and regulatory guidance to accelerate the clinical adoption of new therapeutics and diagnostic technologies.

Tax Incentives Extend Seed Capital Runway, Offering a Cost-Efficient R&D Base in North America

On the tax front, Dr. Lin Tang, Director of Health & Biomedical Industries, Calgary Economic Development, highlighted Alberta’s highly competitive fiscal environment. The province imposes no provincial sales tax and no payroll tax. Its corporate income tax rate stands at just 8%, compared with 11–15% in most other provinces. These advantages help manufacturing and technology companies significantly reduce operating costs.

At the federal level, Canada’s Scientific Research and Experimental Development (SR&ED) program is the country’s largest R&D incentive mechanism. Foreign companies that establish a Canadian subsidiary, typically as a non-Canadian-controlled private corporation, can receive a 15% non-refundable investment tax credit on eligible R&D expenditures. If the entity qualifies as a Canadian-Controlled Private Corporation (CCPC), it becomes eligible for a 35% refundable tax credit. Starting in 2026, this enhanced rate applies to the first CAD 6 million in qualifying expenditures.

In addition, Alberta’s Innovation Employment Grant (IEG) provides supplementary provincial R&D support. Companies conducting eligible R&D activities in Alberta can receive up to a 20% tax credit in their first year. New companies or first-time R&D performers can directly access the full 20% rate, as their baseline expenditure is zero.

When combined, these incentives can significantly improve capital efficiency. CCPC-qualified companies can achieve a total R&D cost recovery rate of up to approximately 55%, while non-CCPC entities reach around 35%. In practical terms, a company investing CAD 1 million in eligible R&D could reduce its net cost to approximately CAD 450,000 under a CCPC structure, or about CAD 650,000 under a non-CCPC structure. This substantially extends the financial runway for early-stage biotech companies and enhances their ability to sustain innovation.

Phoenix: Where Biomedicine and Semiconductors Dance in the Desert

When Silicon Meets Cells: TSMC Sparks MedTech Manufacturing and Advanced Chip Development

Claudia Whitehead, Bioscience Healthcare Program Manager at the City of Phoenix, emphasized, “TSMC’s presence has not only put Phoenix on the global map but opened an unprecedented gateway for cross-sector innovation.” The city’s biotech strategy centers on interdisciplinary convergence, a concept increasingly recognized in recent years. With TSMC’s first Arizona fab now operational, a second facility set for 2026 installation and expected production in 2027, Phoenix has become a critical hub for precision manufacturing and microelectronics in the U.S. According to GPEC, the semiconductor ecosystem directly benefits medical device and biosensor industries. For companies developing wearable health devices, microfluidic chips, or advanced microscopy equipment, Phoenix offers one of the most comprehensive component supply chains nationwide.

A Clinical Proximity Cluster: Mayo Clinic and Discovery Oasis

Phoenix is not only a manufacturing powerhouse but also a center of world-class clinical resources. The Mayo Clinic’s Discovery Oasis expansion in Phoenix has emerged as a flagship for biotech cross-sector innovation. The project adds operating rooms and research beds while tightly linking medical services, research, and advanced medical manufacturing. It attracts industry leaders like W.L. Gore & Associates, creating a seamless pipeline from clinical needs to prototype design and large-scale precision production.

Functionally, Discovery Oasis leverages Mayo Clinic’s clinical resources to operate as a translational accelerator bridging industry and academia. In partnership with Arizona State University, the Health Futures Center integrates medical technology, engineering, and data science. It houses specialized laboratories, including biomedical engineering, strengthening end-to-end capabilities from basic research and clinical applications to commercialization.

Houston: A High-Barrier Accelerator for Medical Startups

Leveraging the World’s Largest Medical Hub to Drive Clinical Trial Capacity

For many biotech companies targeting the U.S. market, R&D is just the starting point. The real challenge lies in clinical trials and navigating the complexities of healthcare reimbursement. Situated at the heart of this ecosystem, the Texas Medical Center (TMC) is the world’s largest medical hub. It includes renowned institutions such as MD Anderson Cancer Center and Baylor College of Medicine. TMC serves as a practical proving ground for biotech and pharmaceutical companies, managing the highest volume of clinical trials in the U.S. annually. This provides vast, diverse patient populations, accelerating trials and supporting the development of precision medicine and treatments for rare diseases.

BioBridge Connects Globally, Curating Startups for U.S. Market Entry

Houston’s unique advantage lies in the TMC BioBridge program, a preferred pathway for international healthcare companies entering the U.S. market. Through a competitive application process called the Global Innovators Launch Pad, selected startup founders participate in a 10-week residency at the TMC Innovation Factory. During this period, they receive comprehensive support to expand in the U.S., including operational infrastructure setup, clinical validation, and funding access. This accelerates the transformation from innovative concept to tangible impact.

In collaboration with South Korea’s Osong Medical Innovation Foundation (KBIOHealth), TMC has extended partnerships to seven countries, including the Netherlands, Australia, the U.K., Denmark, Ireland, and Japan. Since 2016, the BioBridge program has supported over 80 startups in digital health, medical devices, and related fields.

William McKeon, President and CEO of TMC, noted that gene and cell therapies are driving biotech innovation, offering new hope for previously untreatable diseases. Expanding biomanufacturing capacity is critical for translating these therapies into clinical reality. Strategic international collaborations further strengthen TMC’s position in Houston and globally.

Philadelphia: A Pioneer in Cell and Gene Therapy

Leveraging the University of Pennsylvania Legacy, Cell and Gene Therapies Thrive

If avoiding Boston is about finding highly specialized innovation clusters, Philadelphia—nicknamed “Cellicon Valley”—emerges as a top choice. The city benefits from the deep academic tradition of University of Pennsylvania. The world’s first FDA-approved CAR-T therapy, Kymriah, and gene therapy, Luxturna, were both developed here. Led by Carl June, often called the “Father of CAR-T Therapy” and current director of the University’s Cell Immunotherapy Center, the academic expertise and research depth provide continuous innovation and translational momentum.

According to the Colliers 2025 report, the Greater Philadelphia area ranks among the top four biotech markets in the U.S., with its key advantage in talent density. The region produces over 4,000 science graduates annually, including undergraduates and postgraduates. Venture funding reached USD 3.3 billion in 2024, reflecting strong capital interest and active investment in the sector.

Mature CDMO Ecosystem Attracts Pharmaceutical Giants

Philadelphia’s other major strength is its highly developed CDMO (Contract Development and Manufacturing Organization) ecosystem. Many cell therapy products are time-sensitive, and the city has implemented a “Produced Locally, Distributed Locally” model. This reduces physical distance in the real world, dramatically improving logistics efficiency. According to Select Greater Philadelphia, the region hosts over 30 CDMOs specializing in cell and gene therapies. This allows small and mid-sized biotech companies to avoid heavy early-stage capital expenditures on manufacturing facilities while comparing multiple local providers.

Earlier this year (2026), Philadelphia’s industrial standing was further solidified by major corporate investments. Johnson & Johnson announced in February plans to build a next-generation cell therapy manufacturing site in Pennsylvania. Valued in the billions, this project aligns with the state’s economic development strategy. Pennsylvania supports companies through R&D tax credits and the dedicated PA SITES program, optimizing operational costs. For companies focused on regenerative medicine, CDMO services, and cell therapy, Philadelphia’s combined “talent + logistics + policy” advantage clearly sets it apart from other locations.

Puerto Rico: A Caribbean Pharma Hub Carving Its Own Path

Seamless FDA Alignment, Labor Cost Advantages, and Tax Incentives

Puerto Rico’s core competitive edge stems from its comprehensive tax incentive framework under Act 60. Qualifying export-service companies benefit from a fixed corporate income tax rate of approximately 4%. In certain cases, with government approval, rates may be reduced further. Most incentives are granted through long-term tax decrees, typically lasting 15 years with extensions, providing companies with high tax certainty and long-term planning ability. Some policies are designed to extend through 2050, reinforcing Puerto Rico’s stability and predictability as a life sciences investment destination.

The island’s most distinctive advantage is its status as a U.S. unincorporated territory. Locally produced pharmaceuticals are fully regulated by the U.S. Food and Drug Administration and comply with U.S. federal standards. Products are treated as domestic goods for trade and customs purposes, eliminating import tariffs when shipped to the mainland. Coupled with over 50 years of local pharmaceutical tradition, labor costs remain significantly lower than in the continental U.S.

Meeting International Pharma Cold Chain Standards, SJU Airport Logistics Matures

Over the past two years, government and industry partnerships have strengthened the air cargo ecosystem centered on Luis Muñoz Marín International Airport. Several logistics and airline operators have achieved IATA CEIV Pharma certification, aligning operations with global pharmaceutical cold chain standards. These developments have attracted companies targeting the North American market to establish facilities in Puerto Rico. A recent example is PharmaEssentia, whose new facility in Toa Baja is expected to complete certification and commence production in 2027.

Governor Jenniffer González Colón highlighted, “PharmaEssentia’s choice to locate in Puerto Rico showcases the island’s strategic role in U.S. life sciences and manufacturing. This investment strengthens supply chain resilience, creates high-value jobs, and reinforces Puerto Rico’s position in the global biopharma industry.” Meanwhile, Director General Chi-Yu Chou of the Taipei Economic and Cultural Office in Miami noted, “This landmark Taiwan-Puerto Rico investment deepens bilateral connections and strengthens the U.S.-Taiwan pharmaceutical industry footprint, showcasing Taiwan’s biotech capabilities and international potential.”

Investing in North America: What Do Companies Really Need?

Entering the North American market has never been just a numbers game. In the biotech and pharmaceutical industry, there is rarely a zero-risk, zero-cost, maximized-benefit solution. More often, companies must weigh trade-offs, clarify their industry positioning and development stage, acknowledge potential failure rates and opportunity costs, and assess the resources and cost structures required to meet market entry thresholds. Only then can they make rational strategic decisions and truly know both themselves and the competitive landscape.

Each company has unique internal and external reasons for entering North America. Even if Boston or the Bay Area is not the target, multiple diverse and high-potential options exist. Ultimately, success depends not merely on location. The key lies in aligning capital efficiency with strategic goals, placing precise bets, and executing decisions confidently. This ability to make deliberate, well-informed moves is the core competence truly required to “invest in North America.”

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔

Related Post

Medical Korea

Medical Korea 2026: South Korea Deploys $480 Million to Build a Global Clinical Trial Hub

2026-03-20

Prime

[Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector

2026-01-30

Uncategorized

Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition

2026-01-08